I
Ian O. Ellis
Researcher at University of Nottingham
Publications - 1071
Citations - 84964
Ian O. Ellis is an academic researcher from University of Nottingham. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 126, co-authored 1051 publications receiving 75435 citations. Previous affiliations of Ian O. Ellis include Mansoura University & Curie Institute.
Papers
More filters
Journal ArticleDOI
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C. W. Elston,Ian O. Ellis +1 more
TL;DR: The results demonstrate that this method for histological grading provides important prognostic information and, if the grading protocol is followed consistently, reproducible results can be obtained.
Journal ArticleDOI
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis,Christina Curtis,Sohrab P. Shah,Suet-Feung Chin,Gulisa Turashvili,Oscar M. Rueda,Mark J Dunning,Doug Speed,Doug Speed,Andy G. Lynch,Shamith A. Samarajiwa,Yinyin Yuan,Stefan Gräf,Gavin Ha,Gholamreza Haffari,Ali Bashashati,Roslin Russell,Steven McKinney,Anita Langerød,Andrew R. Green,Elena Provenzano,Gordon C. Wishart,Sarah E Pinder,Peter H. Watson,Peter H. Watson,Florian Markowetz,Leigh C. Murphy,Ian O. Ellis,Arnie Purushotham,Arnie Purushotham,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,James D. Brenton,Simon Tavaré,Carlos Caldas,Samuel Aparicio +35 more
TL;DR: The results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome, and identify novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort.
Journal ArticleDOI
Pathological prognostic factors in breast cancer.
Journal ArticleDOI
Prognostic markers in triple-negative breast cancer
Emad A. Rakha,Maysa E. El-Sayed,Andrew R. Green,Andrew H S Lee,John F.R. Robertson,Ian O. Ellis +5 more
TL;DR: Triple‐negative breast cancer (estrogen receptor‐ negative, progesterone receptor‐negative, and HER2‐negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins.